It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mental disorders (MDs), including schizophrenia (SCZ) and bipolar disorder (BD), have attracted special attention from scientists due to their high prevalence and significantly debilitating clinical features. The diagnosis of MDs is still essentially based on clinical interviews, and intensive efforts to introduce biochemical based diagnostic methods have faced several difficulties for implementation in clinics, due to the complexity and still limited knowledge in MDs. In this context, aiming for improving the knowledge in etiology and pathophysiology, many authors have reported several alterations in metabolites in MDs and other brain diseases. After potentially fishing all metabolite biomarkers reported up to now for SCZ and BD, we investigated here the proteins related to these metabolites in order to construct a protein–protein interaction (PPI) network associated with these diseases. We determined the statistically significant clusters in this PPI network and, based on these clusters, we identified 28 significant pathways for SCZ and BDs that essentially compose three groups representing three major systems, namely stress response, energy and neuron systems. By characterizing new pathways with potential to innovate the diagnosis and treatment of psychiatric diseases, the present data may also contribute to the proposal of new intervention for the treatment of still unmet aspects in MDs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Nara Institute of Science and Technology, Ikoma, Japan (GRID:grid.260493.a) (ISNI:0000 0000 9227 2257)
2 Universidade Federal de São Paulo (UNIFESP), Department of Pharmacology, Escola Paulista de Medicina (EPM), São Paulo, Brazil (GRID:grid.411249.b) (ISNI:0000 0001 0514 7202); National Institute for Translational Medicine (INCT-TM, CNPq/FAPESP/CAPES), Ribeirão Preto, Brazil (GRID:grid.411249.b)
3 Universidade Federal de São Paulo (UNIFESP), Department of Pharmacology, Escola Paulista de Medicina (EPM), São Paulo, Brazil (GRID:grid.411249.b) (ISNI:0000 0001 0514 7202)
4 Universidade Estadual de Campinas (Unicamp), Chemical Biology Laboratory, Department of Organic Chemistry, Institute of Chemistry, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)